AB Science ends three studies in multiple sclerosis, other immune conditions

Trial StartnegativemasitinibNegative

AI Analysis

Summary

AB Science has ended three clinical trials testing masitinib in multiple sclerosis and other immune conditions that were previously paused. The company attributed the decision to prioritization rather than safety concerns.

Clinical Trial Data

Outcome Details

Three studies in multiple sclerosis and other immune conditions ended; previously paused studies not resumed due to prioritization

Importance:5/10

Sentiment:

-0.60

clinical trial terminationmasitinibmultiple sclerosisimmunologytyrosine kinase inhibitor

Related Companies

$INTI

Read the original article

Published by BioSpace on July 13, 2026 11:32 AM

Read Original